角膜生物材料在再生眼科中的进展:支架、生物打印与人工角膜技术
本文综述了角膜修复与替代的生物材料策略,涵盖脱细胞基质、胶原支架、3D打印与生物打印构建体、内皮载体系统及合成与生物人工角膜。生物支架可能支持上皮、基质和内皮修复,内皮组织工程早期结果令人鼓舞,人工角膜仍是终末期疾病最成熟的临床选择,但受限于生物整合不完全。常规临床转化的关键障碍包括长期耐久性、光学稳定性、可制造性和监管复杂性。
要点
- 生物支架如脱细胞角膜、胶原植入物和羊膜衍生物可能支持角膜各层修复。
- 3D打印与生物打印可实现更精确的层特异性构建体。
- 人工角膜是终末期疾病最成熟选项,但生物整合不完全限制其应用。
核心结论
- 基于生物材料的角膜重建进入转化时代,层特异性和混合方法可能扩展传统角膜移植以外的治疗选择。
- 持续进展取决于改善生物整合、长期功能耐久性以及使生物材料创新与手术和监管现实对齐。
研究设计与样本
- 文献综述,回顾实验、转化和临床文献中关于角膜重建生物材料平台的研究。
主要发现
- 角膜生物材料正从被动替代物向日益复杂的再生和假体平台发展。
- 生物支架如脱细胞角膜、胶原植入物和羊膜衍生物可能支持上皮、基质和内皮修复。
- 3D打印和生物打印可实现更精确的层特异性构建体。
- 内皮组织工程尤其有前景,生物工程移植物和合成屏障装置显示令人鼓舞的早期结果。
- 人工角膜仍是终末期疾病最临床成熟的选择,但持续受限于生物整合不完全的后遗症。
关键数值与推荐
- 常规临床使用的关键障碍包括长期耐久性、光学稳定性、可制造性和监管复杂性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To review current and emerging biomaterial-based strategies for corneal repair and replacement, with emphasis on biological scaffolds, biofabricated constructs, artificial stromal substitutes, and keratoprosthetic technologies. DESIGN: Literature review. METHODS: Review of experimental, translational, and clinical literature on biomaterial platforms for corneal reconstruction, including decellularized matrices, collagen-based and extracellular matrix-derived scaffolds, 3-dimensional printed and bioprinted constructs, endothelial carrier systems, and synthetic and biologic keratoprostheses, with particular attention to layer-specific applications. RESULTS: Corneal biomaterials are progressing from passive substitutes to increasingly sophisticated regenerative and prosthetic platforms. Biological scaffolds such as decellularized cornea, collagen-based implants, and amniotic membrane derivatives may support epithelial, stromal, and endothelial repair, whereas 3-dimensional printing and bioprinting now enable more precise, layer-specific constructs. Endothelial tissue engineering appears particularly promising, with bioengineered grafts and synthetic barrier devices showing encouraging early results. Keratoprostheses remain the most clinically mature option for end-stage disease but continue to be limited by sequala of incomplete biointegration. Across platforms, key barriers to routine clinical use include long-term durability, optical stability, manufacturability, and regulatory complexity CONCLUSIONS: Biomaterial-based corneal reconstruction is entering a translational era in which layer-specific and hybrid approaches may expand therapeutic options beyond conventional keratoplasty. Continued progress will depend on improving biologic integration, long-term functional durability, and alignment of biomaterials innovation with surgical and regulatory realities.
引用
- Safir M, Chan CC, Mimouni M, et al. Corneal Biomaterials in Regenerative Ophthalmology: Scaffolds, Bioprinting and Keratoprosthetic Technologies. Am J Ophthalmol. 2026. PMID: 42476433. doi:10.1016/j.ajo.2026.07.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。